Genome-wide DNA methylation profiling predicts relapse in childhood B-cell acute lymphoblastic leukaemia

Chapin, J., Wekslezr, B., Magro, C. & Laurence, J. (2012) Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. British Journal of Haematology, 157, 772–774. Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrle, P.A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., Solenthaler, M. & Lammle, B. (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome [see comments]. The New England Journal of Medicine, 339, 1578–1584. Kavanagh, D. & Goodship, T.H. (2010) Atypical hemolytic uremic syndrome. Current Opinion in Hematology, 17, 432–438. Noris, M., Ruggenenti, P., Perna, A., Orisio, S., Caprioli, J., Skerka, C., Vasile, B., Zipfel, P.F. & Remuzzi, G. (1999) Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Journal of American Society of Nephrology, 10, 281–293. Noris, M., Bucchioni, S., Galbusera, M., Donadelli, R., Bresin, E., Castelletti, F., Caprioli, J., Brioschi, S., Scheiflinger, F. & Remuzzi, G. (2005) Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. Journal of American Society of Nephrology, 16, 1177–1183. Reti, M., Farkas, P., Csuka, D., Razso, K., Schlammadinger,A.,Udvardy,M.L.,Madach,K.,Domjan,G., Bereczki,C.,Reusz,G.S., Szabo,A.J.&Prohaszka,Z. (2012) Complement activation in thrombotic thrombocytopenic purpura. Journal of Thrombosis andHaemostasis,10,791–798. Ruiz-Torres, M.P., Casiraghi, F., Galbusera, M., Macconi, D., Gastoldi, S., Todeschini, M., Porrati, F., Belotti, D., Pogliani, E.M., Noris,M.&Remuzzi, G. (2005) Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 93, 443– 452. Sanchez-Corral, P., Gonzalez-Rubio, C., Rodriguez de, C.S. & Lopez-Trascasa, M. (2004) Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Molecular Immunology, 41, 81–84. Stahl, A.L., Vaziri-Sani, F., Heinen, S., Kristoffersson, A.C., Gydell, K.H., Raafat, R., Gutierrez, A., Beringer, O., Zipfel, P.F. & Karpman, D. (2008) Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood, 111, 5307–5315. Tsai, H.M. (2006) The molecular biology of thrombotic microangiopathy. Kidney International, 70, 16–23.